PARP9 also acts as a survival factor in metastatic prostate cancer, head and neck squamous cell carcinoma (HNSCC), and breast cancer in cooperation with DTX3L and PARP14 (see below). Here, DTX3L is linked to head and neck squamous cell carcinoma.